CLINICAL TRIALS PROFILE FOR VUTRISIRAN
✉ Email this page to a colleague
All Clinical Trials for vutrisiran
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03759379 ↗ | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) | Active, not recruiting | Alnylam Pharmaceuticals | Phase 3 | 2019-02-14 | The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran or the reference comparator patisiran during the Treatment Period. The Treatment Period is followed by a Treatment Extension Period during which all participants in the patisiran group will switch to vutrisiran. This study will use the placebo arm of the APOLLO study (NCT01960348) as an external comparator for the primary and most other efficacy endpoints. |
| NCT04153149 ↗ | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Active, not recruiting | Alnylam Pharmaceuticals | Phase 3 | 2019-11-26 | This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy. |
| NCT06679946 ↗ | A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | ENROLLING_BY_INVITATION | Alnylam Pharmaceuticals | PHASE3 | 2024-12-03 | The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran. |
| NCT07223203 ↗ | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy | NOT_YET_RECRUITING | Alnylam Pharmaceuticals | PHASE3 | 2025-12-31 | The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for vutrisiran
Condition Name
| Condition Name for vutrisiran | |
| Intervention | Trials |
| Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | 2 |
| Amyloidosis, Hereditary | 1 |
| hATTR-PN | 1 |
| Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for vutrisiran
Trials by Country
Clinical Trial Progress for vutrisiran
Clinical Trial Phase
Clinical Trial Sponsors for vutrisiran
Sponsor Name
